角膜细胞治疗:微环境的新兴作用
角膜是细胞治疗的理想试验场,其高度有序的层状结构和可及性促成了首个获欧洲药品管理局批准的干细胞疗法。目前已有自体与异体角膜缘及非角膜缘细胞移植、培养的同种异体内皮细胞注射(处于后期临床开发阶段)、基质替代物以及细胞衍生产品(如外泌体)等策略。优化细胞治疗成功率不仅需要高质量培养细胞/产品,周围微环境对移植细胞定植、功能维持及最终恢复角膜组织完整性和透明性同样重要。
要点
- 角膜因高度有序的层状结构和可及性成为细胞治疗的理想试验场。
- 培养的同种异体内皮细胞注射用于内皮失代偿已进入后期临床开发阶段。
- 细胞衍生制品(如不同来源的外泌体)治疗严重角膜疾病已获初步 encouraging 结果。
核心结论
- 优化细胞治疗成功率除需高质量培养细胞/产品外,周围微环境对移植细胞定植、功能维持及恢复角膜组织完整性和透明性同样重要。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 角膜的高度有序结构使特定细胞群分隔于不同层,加上其可及性,促成了首个获欧洲药品管理局批准的干细胞疗法。
- 目前已提出用于自体与异体角膜缘及非角膜缘细胞移植的不同技术。
- 针对Fuchs营养不良等内皮细胞失代偿情况已尝试细胞替代,注射培养的同种异体内皮细胞现处于后期临床开发阶段。
- 近期开发的基质替代物具有优异的整合能力和透明性。
- 不同来源的外泌体等细胞衍生制品已用于严重角膜疾病治疗研究,结果令人鼓舞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cornea is an ideal testing field for cell therapies. Its highly ordered structure, where specific cell populations are sequestered in different layers, together with its accessibility, has allowed the development of the first stem cell-based therapy approved by the European Medicine Agency. Today, different techniques have been proposed for autologous and allogeneic limbal and non-limbal cell transplantation. Cell replacement has also been attempted in cases of endothelial cell decompensation as it occurs in Fuchs dystrophy: injection of cultivated allogeneic endothelial cells is now in advanced phases of clinical development. Recently, stromal substitutes have been developed with excellent integration capability and transparency. Finally, cell-derived products, such as exosomes obtained from different sources, have been investigated for the treatment of severe corneal diseases with encouraging results. Optimization of the success rate of cell therapies obviously requires high-quality cultured cells/products, but the role of the surrounding microenvironment is equally important to allow engraftment of transplanted cells, to preserve their functions and, ultimately, lead to restoration of tissue integrity and transparency of the cornea.
引用
- Suanno G, Genna VG, Maurizi E, et al. Cell therapy in the cornea: The emerging role of microenvironment. Prog Retin Eye Res. 2024. PMID: 38797320. doi:10.1016/j.preteyeres.2024.101275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。